Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRI Growth Rate was 32.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 4.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Arecor Therapeutics was 32.60% per year. The lowest was -89.00% per year. And the median was -41.40% per year.
Arecor Therapeutics (FRA:6UI) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Arecor Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
FRA:6UI vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Arecor Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Arecor Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 32.60% mean?
Arecor Therapeutics (FRA:6UI) has a 3-Year EPS without NRI Growth Rate of 32.60% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Arecor Therapeutics and its competitors. According to the industry distribution chart, Arecor Therapeutics ranks #349 out of 1160 companies in the Biotechnology industry, placing it in the top 30.1%.
Is Arecor Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Arecor Therapeutics' current 3-Year EPS without NRI Growth Rate is 32.60%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Arecor Therapeutics' value of 32.60% is 103.1% above this industry median. Based on the distribution chart, Arecor Therapeutics ranks #349 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arecor Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #349 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Arecor Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Arecor Therapeutics' value of 32.60% is 103.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arecor Therapeutics's current 3-Year EPS without NRI Growth Rate of 32.60% is 103.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Arecor Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arecor Therapeutics's current 3-Year EPS without NRI Growth Rate is 32.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (FRA:6UI) has a current 3-Year EPS without NRI Growth Rate of 32.60%. The stock's GF Value™ is €0.41, compared to a current price of €0.79 — trading 91.5% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 32.60% and 103.1% above the Biotechnology industry median of 16.05. Arecor Therapeutics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Arecor Therapeutics (FRA:6UI), the current 3-Year EPS without NRI Growth Rate is 32.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (FRA:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.79 is trading 91.5% above its estimated GF Value™ of €0.41.
Key valuation signals for FRA:6UI:
3-Year EPS without NRI Growth Rate: 32.60%
GF Value™: €0.41 vs. price of €0.79 (91.5% above fair value)
Industry Position: 103.1% above the Biotechnology median (#349 of 1160)
No single metric tells the full story. See the FRA:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
26GF Score
Get the complete analysis for FRA:6UI
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6UI has been successfully added to your 
